Nov 20, 2026  ·  1 min read

VitriVax raises $87 million to bring its Lyme vaccine into human testing

Missing a follow-up vaccination can leave protection incomplete. VitriVax, a vaccine developer in Boulder, Colorado, wants to make vaccination simpler with a technology designed to deliver protection in a single dose. It has raised $87 million to move its experimental Lyme disease vaccine into its first human trial and develop additional vaccines.

The company is shifting from supplying vaccine technology to developing medicines of its own. Its platform is also designed to keep vaccine ingredients stable, reducing dependence on refrigerated storage. That could help with both completing vaccination and reaching places where cooling is difficult. The immediate test is whether the Lyme vaccine produces the human data needed to support the company's ambitions.

Source  ·  vitrivaxbio.com ↗

  1. Nov 20Google makes Genie 4 generally available in the paid Gemini API
  2. Nov 20Databricks swaps fixed rate limits for adaptive concurrency in cluster creation
  3. Nov 19AI drafts of heart ultrasound reports match human ones, a trial says
  4. Nov 19FCC sets December 17 compliance date for SIM swap fraud rules
  5. Nov 19GAO says four major AI chatbots produced viable attack plans

This is our sketchbook.

Two stoneware cups turned towards each other, as if in conversation

Got a good project?
Let’s work on it together.

Let’s talk →

info@ndot.io · New Jersey · Budapest · Biel